Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Argus Health
Mallinckrodt
Dow
Fuji
Accenture
Merck
Moodys
Johnson and Johnson
Cerilliant
Healthtrust

Generated: August 17, 2017

DrugPatentWatch Database Preview

HYSINGLA Drug Profile

« Back to Dashboard

What is the patent landscape for Hysingla, and what generic Hysingla alternatives are available?

Hysingla is a drug marketed by Purdue Pharma Lp and is included in one NDA. There are thirty patents protecting this drug and two Paragraph IV challenges.

This drug has four hundred and eight patent family members in forty-five countries.

The generic ingredient in HYSINGLA is hydrocodone bitartrate. There are twenty-two drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the hydrocodone bitartrate profile page.

Summary for Tradename: HYSINGLA

Patents:30
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:HYSINGLA at DailyMed

Pharmacology for Tradename: HYSINGLA

Drug ClassOpioid Agonist
Mechanism of ActionOpioid Agonists
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-003Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-004Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-002Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-002Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-006Nov 20, 2014RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Tradename: HYSINGLA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-001Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-005Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-004Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-007Nov 20, 2014► Subscribe► Subscribe
Purdue Pharma Lp
HYSINGLA
hydrocodone bitartrate
TABLET, EXTENDED RELEASE;ORAL206627-002Nov 20, 2014► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for: HYSINGLA

Drugname Dosage Strength RLD Submissiondate
hydrocodone bitartrateExtended-release Tablets20 mg, 60 mg, and 120 mgHysingla ER4/15/2015
hydrocodone bitartrateExtended-release Tablets30 mg, 40 mg, 80 mg, and 100 mgHysingla ER5/8/2015

Non-Orange Book Patents for Tradename: HYSINGLA

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,387,173Pharmaceutical formulation containing gelling agent► Subscribe
7,141,250Pharmaceutical formulation containing bittering agent► Subscribe
9,205,055Controlled release hydrocodone formulations► Subscribe
8,017,148Pharmaceutical formulation containing opioid agonist, opioid antagonist and irritant agent► Subscribe
9,308,170Pharmaceutical formulation containing gelling agent► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: HYSINGLA

Country Document Number Estimated Expiration
Hong Kong1132189► Subscribe
China102688241► Subscribe
Germany502004003234► Subscribe
Spain2417334► Subscribe
Russian Federation2007132975► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Cipla
Julphar
Novartis
US Army
Harvard Business School
Deloitte
US Department of Justice
Colorcon
Covington
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot